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Abstract
Communication difficulties have considerable impact on people with progressive ataxia, yet there are currently no evidence-
based treatments. LSVT LOUD® focuses on the production of healthy vocal loudness whilst also improving breath support,
vocal quality, loudness and articulation in participating patients. This study aimed to investigate whether Lee Silverman Voice
Treatment (LSVT LOUD®) can improve communication effectiveness in these patients. We performed a rater-blinded, single-
arm study investigating LSVTLOUD® treatment in a population of patients with progressive ataxia including Friedreich’s ataxia
(n = 18), spinocerebellar ataxia type 6 (n = 1), idiopathic cerebellar ataxia (n = 1), and spastic paraplegia 7 (n = 1). Twenty-one
patients were recruited to the study, with 19 completing treatment. Sessions were administered via Skype in the LSVT-X format,
meaning two sessions per week over a period of 8 weeks. Assessments included two baseline and two post-treatment measures
and focused on outcome measures covering aspects ranging from physiological function to impact and participation. Results
indicate improvements in patient-perceived outcomes for 14 of the 19 participants, in both speech and psychosocial domains.
Speech data furthermore demonstrate significant improvements in prolonged vowel duration, and voice quality measures.
Intelligibility and naturalness evaluations showed no change post-treatment. Patients reported high acceptability of the treatment
itself, as well as administration by Skype. This is the largest treatment study for people with progressive ataxia published to date.
It provides an indication that LSVT LOUD® can have a positive impact on communication in this patient group and could form
the basis for larger-scale trials.
Keywords Progressive ataxia . Ataxic dysarthria . Voice quality . Speech therapy . Communication participation . Psychosocial
wellbeing
Introduction
Ataxic dysarthria is a motor-speech disorder associated with
cerebellar dysfunction which is prevalent in progressive
ataxias. The characteristics of ataxic dysarthria include impre-
cise articulation, distorted vowels, voice changes, reduced
speech rate, flat prosody and poor respiratory support [1].
These changes lead to reduced speech intelligibility and
communication breakdown. In a recent survey by Ataxia
UK [2], people with progressive ataxia identified speech and
communication problems as one of the top three most trouble-
some symptoms of their disease with significant negative im-
pact on their lives. Whilst our understanding of the nature of
the communication problems experienced by these patients
has improved significantly over time [3–13], a Cochrane
Review on treatment efficacy for progressive ataxia syn-
dromes concluded that “there is insufficient and low or very
low quality evidence from either RCTs or observational stud-
ies to determine the effectiveness of any treatment for speech
disorder” (Vogel et al., p. 1 [14]). Clinicians are therefore
currently unsure of how to deal with ataxic dysarthria.
Vogel et al. [15] recently reported positive outcomes from a
pilot study on speech treatment involving seven patients with
autosomal recessive spastic ataxia of Charlevoix-Saguenay
(ARSACS). Their treatment was home based, supported by
an App that took participants through exercises addressing
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voice production and articulation. Another treatment approach
that has already shown potential to increase communication
efficiency across a range of motor speech disorders is Lee
Silverman Voice Treatment (LSVT LOUD®, [16]). This in-
tervention was originally designed to address the speech def-
icits associated with Parkinson’s disease (PD), in particular
hypophonia, and thus focuses exclusively on increasing the
healthy level of loudness in the patient’s speech. Its effective-
ness has been demonstrated in a number of randomised con-
trolled studies for PD [17–20]. In addition, there are a growing
number of reports on its use in other disorders leading to
dysarthria, such as cerebral palsy [21, 22], traumatic brain
injury and stroke [23, 24], multiple sclerosis [25], and ataxic
dysarthria due to thiamine deficiency [26]. Whilst most LSVT
LOUD® studies have focused on loudness increases as their
primary outcome measure, some also report positive effects
on the wider articulatory system, such as improving breath
support for speech, slowing down the rate, and improving
the voice quality and articulation across these populations
[18, 27, 28]. Although these reports often suffer from small
sample sizes, and sometimes limitations in the breadth and
rigour of their outcome measures, they provide an indication
of the potential for LSVT LOUD® to achieve positive out-
comes in patient populations other than PD and to impact on
speech aspects beyond loudness.
The above research suggests that LSVT LOUD® could be
a suitable intervention to treat people with progressive ataxia.
However, there is a chance that the technique might not be
suitable for all types of ataxic dysarthria, as the presence of
concomitant problems such as fatigue, other health problems,
and, in some ataxia types, impaired auditory processing or
cognitive issues may limit its applicability. Furthermore, it is
necessary to establish whether this approach is suitable to
address the speech problems experienced by this group of
patients, in particular with a view to the spasticity present in
some individuals, for which LSVT LOUD® might be coun-
terproductive. Assessments of the suitability of LSVT
LOUD® for specific ataxia populations are therefore neces-
sary. Consequently, the aim of our study was to perform a
study into the effectiveness and acceptability of LSVT
LOUD® to improve communication in people with dysarthria
due to progressive ataxias.
One problem that has prevented large trials in this area
before is the rare nature of the disorder. With the recent ad-
vances in telehealth technology, one way around this issue is
to provide assessment and intervention remotely. Research
evidence indicating the suitability for this management ap-
proach for acquired motor speech disorders is now relatively
well established, for both assessment [29, 30] and treatment
[31–36]. The studies furthermore report high patient satisfac-
tion ratings. However, this research has mostly focused on
patients with PD, and with predominantly mild motor difficul-
ties. Issues of usability and acceptability are yet to be
investigated for other populations such as people with pro-
gressive ataxia, and across a wider severity spectrum, to iden-
tify potential barriers that need to be considered.
Our research questions were as follows:
(1) Does LSVT LOUD® result in positive changes to com-
munication immediately and 2-month post-treatment in
speakers with progressive ataxia and dysarthria?
(2) Does LSVT LOUD® lead to any undesirable outcomes
such as increased fatigue level, or impact on voice
quality?
(3) What is the patient’s experience of LSVT LOUD® de-
livered by Skype as a treatment regime?
The study is reported according to CONSORT 2010 state-
ment: extension to randomised pilot and feasibility trials [37].
Materials and Methods
Trial Design
This 2-year study was a rater-blinded, single cohort design of
patients with dysarthria due to progressive ataxia, using a
single-study arm—LSVT LOUD® treatment. Eligibility
criteria were adjusted in two ways in order to facilitate recruit-
ment within the given time frame of 15 months. First, we
extended inclusion criteria to speakers with severe dysarthria
providing they successfully completed the stimulability as-
sessment for the intervention approach. Second, the study
was initially restricted to speakers with Friedreich’s ataxia as
per funder focus. However, the study was later opened up to
other types of progressive ataxias, resulting in the inclusion of
3 patients with other forms of this ataxia.
Sample Size
The study was intended to function as a feasibility study for a
larger RCT on the one hand, and already contribute credible
evidence towards treatment of dysarthria in progressive ataxia
on the other. No previous research was available on this pop-
ulation to enable the calculation of an appropriate sample size.
A sample size of 20 was chosen as this was deemed feasible
within the available timescale of 15 months and, in addition,
aligned with the recommendation of patient numbers for stud-
ies following on from single case reports [38]. This permitted
us to already contribute the results of this study to the evidence
base for treatment of ataxic dysarthria. The treating speech
and language therapist (SLT) continuously monitored each
patient for adverse reactions to treatment, in order to allow
for necessary adjustments to be made to the intervention if
necessary. None were reported.
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Participants
Eligibility criteria for the study included a confirmed diagno-
sis of progressive ataxia, the presence of ataxic dysarthria, the
absence of a functional voice disorder other than can be ex-
pected as part of the ataxia, age above 16 years, ability to
follow the assessment and treatment tasks, and availability
of technology to complete assessment and treatment tasks
via Skype.
Advertising took place via the funder website and social
media campaigns, as well as information leaflets posted in a
specialist ataxia clinic at the Sheffield Ataxia Centre, Sheffield
Teaching Hospitals NHS Trust, and University of Sheffield.
As the study was funded jointly by charities in the UK and
Switzerland, recruitment took place in both locations. All par-
ticipants self-selected and contacted the research team to dis-
cover more information about the study. Participants were
provided with study information by email. Suitability to par-
ticipate was established during a phone call and participants
subsequently returned consent forms back to the study team.
Assessment and Treatment
The study included four assessment points, including multiple
baseline assessments (two sessions administered 2 weeks
apart prior to treatment), and two post-therapy assessments,
one within 1 week of completing treatment, and another
8 weeks post-treatment. Assessments were conducted by the
first author who was not involved in the treatment of
participants.
LSVT LOUD® is an intensive treatment that consists of
four 60 min sessions per week over the course of 4 weeks. In
addition, home practice is required: 10 min once a day on
treatment days and twice a day on non-treatment days [17].
However, an extended version (LSVT-X), consisting of 2 ses-
sions a week over 8 weeks, has been shown to result in com-
parable speech outcomes [39]. Following consultation with a
focus group of four people with progressive ataxia, it was
decided to offer participants LSVT-X due to concerns about
impact on fatigue levels of the more intense treatment.
Sessions generally lasted between 50 and 60min and followed
the prescribed treatment schedule and tasks, and participants
were advised to follow the suggested home-practice schedule
[39]. As indicated above, LSVT LOUD® focuses on estab-
lishing a healthy loud voice, which is often lacking in speakers
with PD. Whilst hypophonia has also been reported in people
with ataxia, we anticipated that this would not be the case for
all study participants. Treatment thus varied depending on the
needs of the individual, with a focus on a healthy, unforced
voice production for all speakers, and emphasis on a louder
voice only for those with symptoms of hypophonia. As part of
the aim of this feasibility study was to establish that LSVT
would not be harmful to participants, their voice quality and
other speech characteristics were carefully monitored through-
out the treatment.
Sessions were administered by two SLTs, the first treated
participants 1–3, the second the remaining participants. Both
were experienced, LSVTLOUD®-trained clinicians, who had
treated the minimum recommended number of patients before
becoming involved in the treatment study.
Given the distance of study participants’ homes to the in-
vestigators, both assessment and treatment sessions were de-
livered remotely. In consideration of cost-effectiveness issues
for health services, we did not purchase any tailored software
such as the LSVT LOUD® companion, but instead, used off-
the-shelf, freely available tools for communication (Skype
version 8.48.0.51) and to record assessment sessions
(Audacity® version 2.2.2). In addition, participants were sup-
plied with a low-cost loudness meter (Grandbeing
Schallpegelmesser). They were given access to the
university’s cloud server to securely upload their assessment
recordings after the session. In addition, Skype calls were
audio recorded with their permission as a backup during as-
sessment sessions using the CallNote App.
Assessment Tasks
Both quantitative and qualitative data were collected from
participants to capture as many therapy outcomes as possible.
These covered both speech (assessed in all four sessions) and
psychosocial impact, communication participation, and fa-
tigue measures (collected in assessment session 1 and 3). In
addition, demographic data and medical history were collect-
ed from participants in session 1.
Speech assessment included tasks to assess both individual
speech components andmore natural connected speech. Tasks
were administered in semi-randomised order, structured tasks
were always presented first and in the same order, speech
tasks were presented second, but in randomised order.
Data presented in this paper relates to the following tasks:
(1) vowel prolongation, best of 3 attempts,
(2) a reading passage (The Caterpillar [40])
(3) a 1-min monologue about a topic of choice (e.g. a holi-
day, hobby, or recent memorable event).
Fatigue was measured using the Fatigue Impact Scale (FIS)
[41] to assess whether participation in treatment had adversely
affected the participants’ fatigue levels.
To evaluate self-perception and impact of dysarthria pre-
therapy, we interviewed participants using the standard pre-
treatment questionnaire of the LSVT LOUD® programme,
and also asked them to complete the Voice Handicap Index
(VHI) [42], and the short form of the Communication
Participation ItemBank (CPIB) [43]. The same questionnaires
were used immediately post-treatment (session 3), in addition
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to a further interview where we discussed changes after treat-
ment as well as experience of the treatment process in relation
to schedule, content, and administration by Skype.
Analysis
This paper focuses on the primary outcomesmeasures of max-
imum phonation time and voice quality in vowel prolonga-
tion, and intelligibility and naturalness of connected speech.
Loudness level, which is another frequent outcome measures
in LSVT studies, could not be reported as results were too
unreliable due to participants recording themselves remotely.
Participants had been asked to take several loudness meter
measurements during the session, which were later compared
with the decibel values from the recording. It emerged very
quickly that the relationship between actual decibel level as
indicated on the loudness meter and those of the recordings
were not constant. In addition, some participants were ob-
served to be shifting position considerably during the assess-
ment sessions, thus changing the distance to their micro-
phones. The resulting variations in loudness measures reached
as much as 3 dB, which was deemed too great to be able to
confidently attribute changes in loudness to treatment out-
comes or estimate the average increase in loudness achievable
through LSVT LOUD®. This measure was therefore exclud-
ed from the evaluation.
Secondary outcomes, i.e. measures of psychosocial impact,
fatigue ratings and patient perceptions are also reported. All
examiners were blinded to the time-point of the samples they
analysed.
Vowel Prolongation
The vowel prolongation task was the basis for maximum pho-
nation time (vowel length) and voice quality measures. Vowel
length in milliseconds was determined from oscillographic
and wide-band spectrogram data in Praat ([44], version
6.0.43). In addition, the data were evaluated perceptually by
four experienced SLTs using the GRBAS [45]. This tool pro-
vides scores for Grade (G—overall severity), roughness (R),
breathiness (B), asthenia (A—weak voice), and strain (S).
Listener inter- and intra-rater agreement was very good with
Cronbach’s alpha levels of .836 and .815 respectively.
Reading
The reading task was evaluated for intelligibility and
naturalness. To avoid effects of familiarization with the
speech material, listeners were asked to score reading
samples using direct magnitude estimation (DME).
This method uses a standard, which is given a score
of 100, and asks listeners to rate a given speech sample
in relation to this standard, where a score of 50
represents a sample half as intelligible or natural, and
a score of 200 twice as intelligible or natural as the
standard. The standard was a speaker with moderate
dysarthria who was not included in the study (partici-
pant 12). Samples were presented in groups of 5, i.e.
listeners heard the standard, followed by the recordings
of the four assessment sessions from each participant in
randomised order. The reading samples consisted of an
excerpt from the middle of the reading passage of ap-
proximately 30 s length. Listeners were instructed to
listen to the whole sample before scoring to account
for potential variations in speech quality. To arrive at
an overall score per sample, the geometric mean was
calculated. The listeners consisted of four highly expe-
rienced SLTs familiar with neurodegenerative disorders
different to those who had evaluated the voice samples.
Agreement between listeners for the DME scores for
assessment 1 was high at 0.877 for intelligibility and
0.833 for naturalness ratings.
Monologue
One participant joined the study from Switzerland; she was
sufficiently fluent in English to perform the assessment tasks
and follow treatment instructions. However, she was asked to
use her native French in order to collect a more representative
sample of her natural speech performance. To accommodate
this fact, the monologue data were judged by three naïve
English-French bilingual listeners. The listeners scored sam-
ples of approximately 30 s length from the middle of the
monologue on a 9-point scale that accounts for intelligibility
as well as listener effort [46]. The scores were used to deter-
mine dysarthria severity (Table 1) as well as post-treatment
effects. All naïve listeners had appropriate hearing ability and
no prior experience of ataxic or other types of disordered
speech. They were blinded as to assessment session.
Cronbach’s alpha for listener agreement for the monologue
evaluation of assessment 1 was .939, which indicates high
levels of agreement.
Statistical Analysis
Not all data were distributed normally, and non-parametric
statistics were therefore used throughout, using the Friedman
Test to look for changes across time, and the Wilcoxon
signed-rank test for the post hoc analyses or in cases of paired
comparisons (some vowel prolongation and monologue data).
Bonferroni corrections were applied in cases of multiple com-
parisons. Where correlations were calculated between partic-
ipant characteristics and post-treatment change, the latter rep-
resented the percentage difference between the mean of as-
sessments 1 and 2, and assessment 3. Listener agreement was
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calculated with the Inter-class correlation coefficient as more
than two listeners were involved in each exercise.
Results
Recruitment
The recruitment period lasted 15 months. During this time,
one participant was recruited through the NHS, the rest
through charity advertising and information sharing on social
media sharing by previous participants.
At completion, the study included 18 patients with FRDA,
onewith Spastic Paraplegia 7 (SPG7), onewith Spino-Cerebellar
Ataxia Type 6 (SCA6), and one with idiopathic cerebellar ataxia
(ICA). A further seven people contacted the study team about
participation. Five of these had ataxias other than FRDA and
were added to a waiting list in case the study opened up to these
types of ataxia later. Two of those joined the study at a later date.
One person with FRDA established contact but chose not to
participate due to work pressures, and a further person with
FRDA contacted us too late to be included in the trial.
Baseline Data
Table 1 provides details of patients recruited to the study,
including medical history and dysarthria features. As the ma-
jority of participants lived a considerable distance from the
consulting neurologist and were not due to a routine appoint-
ment during the study duration, no up-to-date neurological
examination could be conducted as part of this study.
Instead, we applied a rough grading of their motor ability as
mild (can walk unaided), moderate (needs walking aids), and
severe (wheelchair bound). Considering the fact that the fea-
sibility assessment focused on the appropriateness of the
speech treatment approach and administration of this via
Skype, this was deemed appropriate for the purpose of this
study. Table 1 shows that the majority of our participants were
rated as showing moderate or severe motor impairment. On
the other hand, most had a mild-to-moderate level of speech
Table 1 Participant details
Participant Age Gender Diagnosis Years since
diagnosis
Motor
impairment
Intelligibility deficit in
monologue (0–9 scale)
1 45 M FRDA 17 moderate 7.5 mild
2 32 F FRDA 22 severe 2 severe
3 36 F FRDA 25 severe 2 severe
4 52 M FRDA 14 moderate 6.5 mild - moderate
5 40 M FRDA 24 severe NA
6 59 F FRDA 46 moderate 4 moderate
7 23 F FRDA 13 moderate 7.5 mild
8 54 F FRDA 10 moderate 8.5 normal
9 75 F FRDA 17 severe 7.5 mild
10 31 F FRDA 22 moderate 7 mild - moderate
11 40 M FRDA 21 severe 9 normal
12 32 M FRDA 21 severe 5.5 moderate
13 25 M FRDA 10 moderate 3.5 moderate - severe
14 48 F FRDA 30 moderate 5 moderate
15 29 M FRDA 21 severe 5.5 moderate
16 19 M FRDA 9 moderate 5 moderate
17 31 F FRDA 22 severe 4.5 moderate
18 71 F FRDA 12 moderate 7 mild moderate
19 49 M SPG7 5 moderate 5.5 moderate
20 70 M ICA 12 moderate 6.5 mild - moderate
21 73 M SCA6 19 moderate 4 moderate
Summary: Mean: 44.5
SD: 17.3
M: n = 11
F: n = 10
Mean: 18.7
SD: 8.9
Moderate
n = 13
Severe n = 8
Mean: 5.5
SD: 2.1
M male, F female; FRDA Friedreich’s Ataxia, SCA6 Spino-Cerebellar Ataxia Type 6, ICA Idiopathic Cerebella
Ataxia; SPG7 Spastic Paraplegia 7
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impairment, with only a few located at the lower moderate to
severe end of the spectrum.
Adherence
Of the 21 patients recruited, 20 commenced and 19 completed
treatment (Table 2). One speaker with FRDA provided con-
sent, but then became too unwell to participate and no assess-
ment data were collected from him. One other participant
(participant 12) commenced treatment which was put on hold
after 6 sessions due to suspicion of vocal pathology. This only
became apparent after his speech performance began to im-
prove as a result of treatment, and he was able to produce a
prolonged sound long and loud enough to highlight potential
problems with his voice. The participant was advised to seek
ENT examination to ensure speech treatment would not ad-
versely affect his vocal health. The resulting delay meant that
he could not rejoin treatment and he was therefore categorised
as a non-completion. A further participant became hoarse dur-
ing the second assessment. It was initially assumed that this
was due to a cold and treatment was started, but the problem
persisted. He was again advised to seek medical examination
and rejoined the study at a later date.
All but four of the participants experienced gaps in the
treatment regime due to ill health or holidays. This could take
the form of single sessions within a week or interruptions of
1 week or longer. When individual sessions were missed, it
was attempted to reschedule them, but this was not possible in
all cases. Twelve of the 19 participants completing treatment
received the full number of sessions, two participants missed 1
session, three participants 2 sessions, and two participants 3
sessions. Longer interruptions tended to last for 1 to 2 weeks,
but extended to 4 weeks in one case.
Numbers Analysed
Overall, most data are complete across tasks and measures.
VHI questionnaire data are missing from 3 participants due to
a clerical error. One participant had visual problems and was
therefore unable to complete the reading assessment.
Outcomes
Prolonged Vowel Measures
Maximum phonation time shows a significant change over time
(Friedman test: p = .003, df = 3). Bonferroni corrections were
applied to the post hoc tests in relation to two hypotheses; no
change between assessments 1 and 2, and 3 and 4 (2 compar-
isons, p < .025), and change between pre- and post-treatment
assessments (4 comparisons, p < 0.0125). The post hoc tests
indicate no significant difference between the two pre-
treatment (p = .116) or post-treatment sessions (p = .081). On
the other hand, comparison between pre- and post-treatment
sessions shows significant differences between the session 2
and both post-treatment assessments (session 2–3: p = .001;
session 2–4: p = .001), whereas comparisons between sessions
1 and 3 and 4 were not significant (session 1–3: p = 0.014;
session 1–4: p = .131). Table 3 provides the group means and
standard deviations for each assessment point. As suggested by
the high standard deviation, performance varied considerably
between participants, with the poorest performer only achieving
a length of 2.7 s in session 1, and the highest performer 23.6 s,
Table 2 Adherence data, indicating number of sessions attended and
number of interruptions (target number of sessions—16)
Participant No. of sessions
administered
No. of sessions
rescheduled
No. of interruptions in
treatment > 1 session
1 16
2 16 2
3 16 1
4 15 1 1
5 No treatment
6 16 1
7 16
8 14 2 2
9 16 1
10 16 1
11 13
12 5—discontinued
13 16
14 13 1
15 14
16 16 1
17 16
18 16 2
19 16 1
20 14
21 15 1
Table 3 Prolonged vowel data: vowel length and GRBAS scores
Session 1 2 3 4
Length 9.80 (6.56) 8.92 (6.30) 12.78 (5.98) 11.62 (4.88)
G 1.95 (0.52) 1.74 (0.60) 1.61 (0.63) 1.33 (0.57)
R 1.12 (0.74) 1.09 (0.61) 0.70 (0.56) 0.91 (0.52)
B 0.83 (0.56) 0.88 (0.59) 0.58 (0.35) 0.42 (0.46)
A 0.96 (0.72) 0.96 (0.56) 0.45 (0.38) 0.45 (0.41)
S 1.37 (0.75) 1.24 (0.67) 1.34 (0.74) 0.93 (0.55)
Values denote means and (standard deviations) for vowel length (in ms)
and GRBAS scores (0–5 scale)
G grade, R roughness, B breathiness, A asthenia, S strain
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with four participants performing within the normal range
([47]). The range of improvements varied as well. A compari-
son of the mean of assessments 1 and 2 with assessment 3
indicates that 13 participants improved more than 20%, the
largest change showing an increase from 2.7 to 16.2 s. At the
same time, six speakers changed their vowel length by less than
5% or performed slightly worse. These included the four
speakers who already performed within the normal range, as
well as one participant with a pre-existing lung condition that
limited his performance. If those five speakers are excluded
from the data set the pre- to post-treatment comparisons all
become significant (session 1–3: p = .002; session 1–4:
p = .001; session 2–3: p = .002; session 2–4: p = .003).
In summary, of the 13 participants who were expected to
improve in their maximum phonation time, twelve achieved this.
Furthermore, participant 12, who had his treatment terminated
early and is thus not included in this analysis, also demonstrated
noticeable improvements inmaximum phonation timewithin the
first week of treatment. The data thus suggests that LSVT® was
generally successful in improving participants’ breath support
for speech where this was reduced. Non-FRDA partici-
pants performed well within the range of the remaining
speakers in relation to their baseline performance and
degree of change after treatment, thus not suggesting
any influence of genotype on maximum phonation time.
The second measure taken from the vowel prolongation task
was perceptual voice quality as reflected by the GRBAS evalu-
ation (Table 3). Although the scores were relatively mild across
the group, none of the participants were scored by all listeners as
having a value of 0 (no impairment) across any of the dimen-
sions pre-treatment. The highest score awarded was 3, indicating
at most a moderate impairment of voice quality. For the statisti-
cal analysis, Bonferroni corrections were set as p < .010 for the
Friedman test (5 comparisons), and as specified for maximum
phonation time above for the post hoc tests. The Friedman test
results indicate significant change across all variables but Strain
(Table 4). Post hoc tests show significant differences from at
least one of the pre-treatment sessions to post-treatment, with
no significant change between the two pre-treatment or post-
treatment sessions. The change over time for Grade,
Roughness, Breathiness, and Asthenia can thus be attributed to
a treatment effect. As an indication of the range of performance,
the comparison of the mean values of assessment 1 and 2 with
assessment 3 showed improvements in overall voice quality
(Grade) for eight participants, in Roughness for 15, Breathiness
for 14 and Asthenia for 16 speakers. The remaining participants
showed no or small negative change. Patterns for Strain were
more variable, with only eight participants showing improve-
ment, five having no or minimal change, and a further four
showing some more noticeable deterioration, resulting in the
statistically not significant result. Comments from listeners sug-
gest that this might have been due to these speakers forcing their
voice to some degree towards the end of the prolonged vowel to
extend their duration as much as possible.
Figure 1 provides a visual example of some of the positive
changes perceived by the listeners. Figure 1a (participant 1, pre-
treatment) shows an unsteady pitch, large variations in loudness,
and some aperiodicity of phonation, resulting in a perception of
roughness. Figure 1b (participant 1, post-treatment), on the other
hand, demonstrates a smoother, more periodic vowel phonation
with steady pitch and loudness throughout, reflecting better con-
trol of the vocal mechanism. There was again no evidence in an
influence of genotype on voice quality, and the range of scores
and degree of change from pre- to post-treatment was compara-
ble across participants with FRDA and other types of ataxia.
Whilst there was no evidence of influence of genotype on the
above measures, a correlational analysis demonstrated a signifi-
cant relationship between severity (as measured by monologue
intelligibility) and maximum phonation time (r = .646, p = .003),
as well as betweenmaximumphonation time and voice quality at
assessment 1 as reflected by the Grade score (r = − .540,
p = .017). However, there was no significant correlation between
severity and the degree of change in maximum phonation time
(r= − .276, p = .253) or Grade (r = .067, p = .785) after treatment
(percentage change from assessment 1 to 3), or between maxi-
mum phonation and the change in Grade (r = .270, p = .263).
Table 4 Statistical results for pre-
and post-treatment comparisons Friedman Pre-treatment Pre- to immediately
post-treatment
Pre- to 8 weeks post-
treatment
Post-treatment
Session: 1–2 1–3 2–3 1–4 2–4 3–4
Length .003 .116 .014 .001 .131 .011 .081
G < 0.001 .499 .002 .056 < .001 .001 .043
R 0.009 .673 .006 .008 .108 .078 .028
B < 0.001 .839 .048 .028 < .001 .001 .140
A < 0.001 .499 .002 .056 < .001 .001 .043
S 0.466 --- --- --- --- --- ---
All values denote p values. Significant results are marked in italics
G grade, R roughness, B breathiness, A asthenia, S strain
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The data thus show that participants with milder levels of dysar-
thria had longer maximum phonation time and better voice qual-
ity. However, baseline severity did not necessarily predict to
what degree those measures would improve.
Intelligibility and Naturalness
Figure 2 shows the results for intelligibility and naturalness in
the reading passage for expert ratings across all four time
points. The Friedman test across did not indicate any signifi-
cant changes over time in intelligibility or naturalness
(p = .813 and p = .989 respectively). A similar lack of change
in intelligibility was identified by the naïve listeners in the
monologue (p = .333). Qualitative inspection of these data
reveals relatively small deviations from baseline, indicating
that this was due to little change being perceived rather than
change occurring in different directions. This applied equally
to all participants, with no effects of genotype noticeable.
There was also no significant correlation between severity
and extent of change in intelligibility in reading (r = .059,
p = .816) or the monologue (r = −.006, p = .980), i.e. the de-
gree or direction of change did not depend on the baseline
intelligibility level of the speaker.
Psychosocial Outcomes and Participant Perceptions
None of the questionnaires showed any significant differences
between pre and post-treatment sessions (CBIP: p = .154,
Fig. 1 Oscillogram and
spectrogram plots of prolonged
vowel for session 1 (a) and
session 4 (b) for participant 1. The
red line represents the loudness
contour, and the yellow line the
pitch contour
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VHI: p = .056, VAS: p = .778). On the other hand, post-
treatment interviews indicated that the majority of participants
felt their communication had improved after treatment. Most
participants indicated noticeable improvements in at least two
speech or psychological dimensions; however, two patients
only described minimal changes (participants 4 and 9) and
two further patients reported no changes post-treatment (par-
ticipants 10 and 14). The most common dimensions highlight-
ed by those who reported treatment effects were improved
loudness and/or better control over their voice (14/17 pa-
tients)—“Because of the changes in my voice I used to sound
anxious in meetings, but now that I have the strategies my
presentation went really well”; “It’s helped me to control
my voice”; clearer speech and/or less need to repeat (13/17
patients), and being able to speak in longer phrases, for a
longer time or both (13/17 patients)—“Before, it took a lot
more effort to pronounce words”; “I find it easier to complete
all the syllables now”; and “Before, I’d say “I can’t be both-
ered”, but now I’ve been able to be more involved in
conversation”. In about 50% of these cases, these reports were
corroborated by friends and family who in some cases were
unaware of the fact that the participant had undergone treat-
ment recently—“I recently met with some college friends who
I’d not seen for 2 years and they commented I sounded better
than last time”. An interesting finding in relation to loudness
was that some participants initially reported worries about
sounding aggressive when speaking at a normal volume, and
consciously reduced their speaking volume. Rather than
effecting physiological change to improve hypophonia, the
treatment addressed a psychological dimension in these
speakers. A further psychological outcome that was frequently
highlighted was an increase in confidence or reduction in anx-
iety, in many cases leading to increased communication par-
ticipation—“I’m not worried that people will ask me to repeat
anymore” and “I used to avoid phone conversations but I’m
fairly confident now”. Despite the lack of significant changes
in the questionnaire data, participant responses thus indicated
positive outcomes after treatment for both speech and psycho-
social aspects. As demonstrated in Table 5, there was no
noticeable difference in terms of reported outcomes for the
non-FRDA participants (speakers 19, 20, and 21).
Acceptability of LSVT LOUD® and Skype Delivery
The post-treatment interview also questioned participants
about their experiences of the treatment programme and the
remote provision using Skype. All respondents indicated that
the treatment had been relevant and addressed the areas of
speech impairment that they were concerned about. Two par-
ticipants indicated they would have liked to work more on
articulation. All were able to cope well with the two sessions
per week regime, there was variable response in relation to
whether they would have managed the usual four sessions a
week as treatment was tiring. There was also a wide variation
in terms of home practice adherence, with some participants
indicating practising the recommended 4–5 times a week, and
others only managing once or twice in addition to their ther-
apy sessions.
All but one participant indicated that they preferred remote
treatment to face-to-face sessions. The main reasons provided
were reduced fatigue from not having to travel to clinic, great-
er flexibility to fit sessions around other activities and/or re-
duced travel time, particularly for those still in employment.
None of the respondents felt that patient–therapist relation-
ships had been impacted by the remote treatment, or that tech-
nical problems affected treatment provision. They did indicate
though that the remote assessment had been more of a prob-
lem in terms of dealing with the technology to record their
speech and upload the data.
Harms
None of the participants reported any harm as a result of par-
ticipating in this trial, and there was no evidence of negative
sequelae from observations during intervention or highlighted
by the subsequent data analysis either. In particular, the hy-
pothesis that voice quality might be adversely affected by the
treatment was rejected by our analysis.
All participants had reported issues with fatigue in the ini-
tial interview, which was frequently mentioned as one of the
three most prominent issues affecting their lives. The mean
overall score (VAFS) on the Fatigue Impact Scale (FIS) was
x = 5.17 (SD = 2.4, range 3–10 where 0 is worst and 10 is
normal). Scores for the nine individual FIS categories did
not change significantly from pre- to post-therapy (p = .251).
There was therefore no indication that treatment had adversely
affected the participants’ fatigue levels. Patient reports in the
post-treatment interview confirmed this fact, although a num-
ber of participants reported that the treatment had been
strenuous.
Fig. 2 Intelligibility and naturalness DME ratings (mean and SD) for the
reading samples across all four assessment sessions
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Discussion
This feasibility study presents the outcomes of LSVT
LOUD® treatment for patients with progressive ataxia.
Overall, study outcomes were positive for measures related
to voice quality and breath support for speech as measured
by vowel prolongation. Formal measures of intelligibility or
psychosocial impact did not show any statistically significant
changes post-intervention. However, patient reports in inter-
views suggested beneficial effects on both dimensions for the
majority of participants. Furthermore, participants reported
that LSVT LOUD® was an appropriate and acceptable inter-
vention approach, and particularly liked the remote adminis-
tration via Skype. Neither formal measures nor patient reports
indicated any negative impact on fatigue levels with the cur-
rent LSVT-X treatment regime.
There is only one other study to date that has investigated the
effects of speech treatment in a group of seven speakers with
progressive ataxia [15]. This study’s approach included a wider
range of treatment targets, including voice and loudness produc-
tion, as well as articulatory practice. The authors report positive
outcomes for intelligibility and naturalness, but not for vocal con-
trol, although this study did not go into the same amount of detail
of analysis as the current investigation. The only other comparable
study is the single case report of non-progressive ataxia [26].
Again, our intelligibility outcomes do not match those reported
for this case; however, they compare favourably with the vowel
prolongation measures and self-reported psychosocial benefits.
Whilst the GRBAS ratings for our participant group suggested
mostly milder levels of dysphonia in line with the literature, im-
proving voice quality and vocal stability should still be a consid-
eration in treatment planning ([9]). In this regard, our results on
improved voice quality were positive. One of the reservations of
using LSVTLOUD®with this patient group had been a possibly
contraindication of the effortful therapeutic approach in the pres-
ence of spasticity, which can be a feature in FRDA.However, our
results suggest that not only did LSVT LOUD® not cause any
harm in this respect, it actually had beneficial consequences for
voice quality. In line with previous reports on other dysarthria
types (e.g. [24, 31]), LSVT LOUD® thus represents a viable
option to improve vocal stability in ataxia. Participant comments
furthermore suggested wider benefits to communication as a re-
sult of the noted improvements in vocal quality such as increased
communication participation due to the reduced effort required for
communication or the increased control over their voice.
The results on improved breath support as reflected in in-
creased vowel prolongation were furthermore encouraging.
Whilst we would have liked to capture the impact of this in
connected speech, this was not possible, as qualitative inspec-
tion of the data indicated that participants both increased and
reduced their phrase lengths after treatment. The latter was not
due to any negative impact of treatment, but simply the fact that
Table 5 Patient perceptions of
changes in communication and
psychosocial dimensions post-
therapy
Participant Louder Clearer Longer
phrases/
speaking
time
Better
pacing/
breath man-
agement
Better
pitch/
loudness
control
Corroboration
by others
Increased
confidence/
reduced anx-
iety
1 1 1 1
2 1 1 1 1 1 1
3 1 1 1 1 1
4 1 1 1
6 1 1 1 1
7 1 1
8 1 1 1 1 1
9 1 1
10
11 1 1 1 1 1
13 1 1 1 1 1
14
15 1 1 1
16 1 1 1 1 1
17 1 1
18 1 1 1 1 1
19 1 1 1
20 1 1 1
21 1 1
Total 14 13 13 4 2 7 10
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they had learnt to manage their breath support better by placing
more pauses in strategic places. This, however, meant that
phrase length was not an appropriate outcome measure to use
in this study. A number of participants commented positively
on this feature during interview though, and more importantly,
spoke about the ability to take part in conversation for longer.
The lack of improvement in intelligibility and naturalness
scores was unexpected, but there are several possible expla-
nations for this, the first being issues with adherence. Our
participants experienced a high number of interruptions and
gaps in their treatment course (Table 2), which could have
affected their outcomes. On the other hand, whilst Vogel
et al. [15] report a 100% completion rate of their protocol,
no information is provided about interruptions. Sapir et al.
[26] do not mention adherence being an issue in their case
report. In addition, Vogel et al. [15] used a home practice
App which ensured regular practice by participants. This
was not monitored formally in our study, but judging from
patient reports, the suggested regime was not always main-
tained. Finally, Vogel et al.’s [15] participant group was of
lower severity level than included in this study. Whilst we
could not identify any relationship between level of speech
impairment and post-treatment change in our study, the lower
level of disability could have further contributed to greater
adherence and thus possibly better outcomes in their study.
Other factors include influences of recording quality on listener
ratings, or the fact that participants might not have been feeling
well at the time of the post-treatment assessment, which was
reported by some individuals. In addition, many participants
struggled with the recording procedure and could thus have been
distracted from the speech tasks during assessment, and as a result
might not have used the strategies practiced in treatment during
the assessment sessions. The fact that other people commented on
improvements and participants reported a reduced need to repeat
themselves could indicate that they used their strategies in real-life
situations when they needed to make themselves understood, but
not during the rather artificial assessment context. Finally, it
should be noted that intelligibility improvement in PD as a result
of LSVT LOUD® is often associated with the resulting increase
in loudness. As the current participant sample did not demonstrate
significant levels of hypophonia at baseline on the whole, this
factor was not a contributor here. Instead, we hypothesised that
the additional effort associated with loud voice production might
have resulted in improved intelligibility, but this was not the case.
It is thus possible that the intelligibility deficits caused by the poor
coordination ofmovement associatedwith ataxic dysarthria is less
likely to respond to increased effort in speech production than the
reduced range or speed of movement reported in PD (e.g. [31]) or
non-progressive dysarthria ([23, 27]).
A further unexpected result was the lack of improvement for
the scores of the formal questionnaires on impact and partici-
pation in view of the positive reports on treatment outcomes
emerging from the patient interviews. Again, there are potential
explanations for this finding. First, the scoring of these ques-
tionnaires might have been insufficiently sophisticated to cap-
ture the perceived change. For example, the CPIB uses four
categories ranging from “not at all” to “a little”, “quite a bit”
and “very much”, which might not have picked up some small-
er improvements. Second, the questions might not necessarily
have picked up on the dimensions that improved in participants,
e.g. the amount of interference of their dysarthria in talking to
people they do not know or talking on the phonemight not have
changed, but they reported feeling more confident about it,
which is not captured by the questionnaire. Finally, the partic-
ipants did not have their initial responses available when scor-
ing the post-treatment questionnaires and a change of aware-
ness or perception of certain features as a result of the treatment
process could thus have led to scoring an item as being worse
on the questionnaire when the participant actually expressed the
opinion that this had improved in their interview. An important
point to remember is that these questionnaires were not de-
signed as outcome measures but as status questionnaires,
intended to highlight to the clinician what impact the speech
or voice disorder is having on the patient. The current study
suggests that their use as outcome measures needs to be con-
sidered carefully and ideally be supplemented with qualitative
interview data from participants.
Limitations and Interpretation
There were some limitations to our paradigm that might have
impacted on our results and/or should be addressed in future
larger trials. First, running this study under typical health service
provider conditions without any specialised software has impact-
ed on the fidelity of the outcome measures. This relates in par-
ticular to the quality of the speech recordings and the accuracy of
the loudness measures. Although there was sufficient good-
quality material available for each participant to capture our out-
come measures, part of the data had to be disregarded at times as
the quality was too low. Whilst the loudness readings taken by
the participants were sufficiently accurate for treatment purposes,
they fluctuated too much by e.g. speakers shifting position and
thus distance to the microphone to yield reliable data necessary
for the outcome measurement. We suggest that any future study
at least supplies participants with lapel or headmounted, calibrat-
ed microphones to ensure good quality and accurate data collec-
tion or, preferably, performs assessment face to face, as partici-
pants reported this part of the study as taxing.
Another methodological issue that should be addressed in a
future study is the way the qualitative data are collected. The
current interviews did not refer to the questionnaire data, as
not all participants returned this information in time for the
first post-treatment assessment session. It was thus not possi-
ble to explore potential discrepancies between the interview
and questionnaire data. One reason why interview reports
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were more positive than formal ratings could of course be that
participants felt under some pressure to report positive out-
comes as they were interviewed by one of the study investi-
gators (though not the person who provided the treatment).
However, whilst this might explain some of the differences,
we feel that the interview data are sufficiently true to be used
as an outcome as (1) participants also reported negative issues
or the fact that nothing had changed, and (2) reports of what
had changed in their communication were sufficiently consis-
tent across participants to suggest that these were real changes
experienced, as no prompts were given as to what aspects
might have altered in their speech. As indicated above, we
therefore believe that the issue lay with the questionnaires
rather than interview data, and that they should be cross-
checked with patient interviews.
The final point that should be considered in a future trial is the
fact that the choice of LSVT-X (8-week period) possibly led to
more cancellations due to participants feeling unwell, going on
holiday or having to pursue other appointments than is usually
reported for traditional LSVT LOUD® (4-week period). Whilst
there were mixed reports from participants on whether they felt
they could have dealt with the more intensive programme, this
option should not be disregarded in future considerations.
On the other hand, treatment delivery by Skype was fully
supported by all participants. Only one person expressed a
preference for face-to-face therapy, although they still felt that
the Skype sessions provided the same level of therapeutic
benefit. Others expressed that they could not have participated
in treatment had it not been delivered remotely, particularly
those who were still in employment and would not have been
able to fit the hours into their work schedule, and those suf-
fering from severe fatigue issues.
Conclusion
Our study represents the largest clinical trial conducted on peo-
ple with progressive ataxia to date. Post-treatment comparisons
indicate improvements in physiological functioning (voice
quality, breath support), as well as speech production, commu-
nication participation, and some psychological dimensions
(confidence, anxiety) as perceived by the participants, in both
speakers with FRDA and other types of progressive ataxia.
Whilst the latter could potentially be attributed to a placebo
effect, the physiological changes and some of the reported
speech outcomes are more likely to be a result of speech inter-
vention, thus indicating positive treatment effects. Intelligibility
and naturalness as rated by unfamiliar listeners did not change
significantly. However, whilst increased intelligibility is often
regarded as an important indicator of improved communica-
tion, our patient-reported outcomes suggest that this can also
be reflected by other measures, such as lessened anxiety whilst
communicating, or reduced effort required for speaking.
In the current climate where many health professionals are
unsure about how best to support patients with progressive atax-
ia, we would therefore argue that our study has demonstrated a
potential for positive outcomes for communication and psycho-
social well-being following LSVT LOUD® for this group. This
now needs to be investigatedwith larger trials to establishwheth-
er similar results could be achieved with less intensive interven-
tions such as traditional phonatory treatment, and whether other
approaches would be more effective in also addressing intelligi-
bility and naturalness of speech in people with ataxia. However,
whilst we await the outcomes of larger randomised controlled
trials such as [48], we would suggest that SLTs can consider
providing LSVT LOUD® treatment for patient with progressive
ataxias, provided that the impact of the treatment is closely mon-
itored for improvements and adverse effects.
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